A relationship between miRNA expressions and clinico-histopathological characteristics, namely tumor size, grade and histology, regional lymph node involvement, HR (estrogen and progesterone) and HER2 status, Ki-67 expression and CTC presence, was evaluated in 128 patients suffering from invasive BC. This evidence concerns the gene ERBB2 and breast cancer.